Eisai Clinical Trials

A 24-week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson’s Disease Patients with Dementia.

E2020-E044-316

Study Overview

E2020
donepezil
NCT00165815
Aug 2002 - Jul 2005
Dementia With Parkinson’s Disease
PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

  • Males and females (age 40 years and over)

  • Completed

  • Phase 3

  • Germany, Ireland See more

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Dubois B et al. Donepezil in Parkinson’s disease dementia: A randomized, double-blind efficacy and safety study. Movement Disorders 2012; 27.10: 1230-1238. DOI: http://dx.doi.org/10.1002/mds.25098

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR